FDA drafts plan for easier interchangeable biosimilar drugs
Published Date: 9/18/2026
Notice
Summary
The FDA just shared a draft plan to help make interchangeable biosimilar drugs easier to develop and approve. This affects drug makers and patients who want more affordable medicine options. The FDA wants your feedback by November 17, 2026, before finalizing the plan, which supports innovation and smoother drug approvals through 2027.
Analyzed Economic Effects
3 provisions identified: 3 benefits, 0 costs, 0 mixed.
Draft Strategy to Support Biosimilars
The FDA published a draft Strategy Document that summarizes the September 19, 2025 public workshop and describes FDA's future directions to support development of interchangeable biosimilar products under the BsUFA III commitments for fiscal years 2023 through 2027. The Agency is accepting public comments on the draft through November 17, 2026.
Education for Patients and Providers
FDA says it will provide educational resources for healthcare providers and patients about interchangeable biosimilar products to help build confidence in their safety and effectiveness. The draft Strategy Document summarizes this planned focus and is open for public comment through November 17, 2026.
Focus on Science and Human Factors
The draft Strategy Document says FDA will continue to follow evolving science and address scientific topics such as analytical data considerations and user interface and human factors when supporting interchangeable biosimilar development. These areas were discussed at the September 19, 2025 workshop and are summarized in the draft available for comment until November 17, 2026.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-19181, Electronic Submission Template for Medical Device Premarket Approval Applications (PMAs); Draft Guidance for Industry and Food and Drug Administration Staff; Availability
The FDA just dropped a draft guide to help medical device makers submit their big approval applications electronically. This new template aims to make submissions easier, faster, and more consistent for companies working with the FDA’s device and biologics centers. If you’re in the medical device game, check it out and send your feedback by November 17, 2026—no fees or changes yet, just a heads-up for smoother future filings!
2026-19141, Target Animal Safety Evaluation for Veterinary Monoclonal Antibody Products; Draft Guidance for Industry; Availability
The FDA just released a draft guide to help vets and companies test the safety of special animal medicines called veterinary monoclonal antibodies. This new guide aims to make safety testing easier and more consistent worldwide, helping get these medicines to animals faster and safer. If you’re involved in making or testing these products, send your feedback by November 17, 2026, to shape the final rules!
2026-19074, Medical Devices; Exemption From Premarket Notification: Radiology Computer-Aided Detection and/or Diagnosis Devices and Computer-Aided Triage and Notification Devices
The FDA has decided NOT to exempt certain radiology computer software devices from premarket review, meaning these devices still need FDA approval before hitting the market. This affects companies making cancer detection and medical image analysis software, keeping safety checks in place. The rule takes effect on September 17, 2026, so businesses should plan accordingly to avoid delays or extra costs.
Previous / Next Documents
Previous: 2026-19165, Certain Gyro-Stabilized Electric Unicycles and Components Thereof and Products Containing the Same; Notice of a Commission Determination Not To Review an Initial Determination Granting Complainants' Unopposed Motion To Amend the Complaint and Notice of Investigation
The U.S. International Trade Commission is moving forward with a case about gyro-stabilized electric unicycles, adding a new company, LeaperKim Coyote, to the investigation. This affects companies importing or selling these unicycles in the U.S., with potential impacts on sales and patents. The case started in March 2026 and is now expanding, signaling serious attention to patent rights and market control.
Next: 2026-19167, U.S. Strategic Command Strategic Advisory Group; Notice of Federal Advisory Committee Closed Meeting; Republication
The U.S. Strategic Command Strategic Advisory Group will hold a secret meeting on September 21-22, 2026, to discuss important military and technology topics like nuclear stockpiles and new threats. This meeting affects military leaders and advisors but won’t cost extra money or change public rules. The notice was reissued because they missed a public announcement deadline but got a special waiver to proceed anyway.